NCT07557706
Using taVNS to Modulate Cardiovascular Function in Individuals With Neurologic Disease
At risk: Primary completion moved 11 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Jul 31, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 11 words
- Secondary endpoints: details revised at 4 of 5 entries
- Site contact updated
- Publications: details revised at 1 of 1 entry
- Notable Phase changed: Not applicable → Phase 1v2
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (5)
Arms and interventions
Active taVNS on Visit 2, Sham taVNS on Visit 3. Active taVNS is delivered at 30 Hz, 250 µs, 0.1-4 mA for 15 minutes. Sham taVNS is delivered at 0 mA output for 15 minutes. A minimum washout period of 48 hours will be observed between visits.
Sham taVNS on Visit 2, Active taVNS on Visit 3. Active taVNS is delivered at 30 Hz, 250 µs, 1-4 mA for 15 minutes. Sham taVNS is delivered at 0 mA output for 15 minutes. A minimum washout period of 48 hours will be observed between visits
Devices: transcutaneous auricular vagus nerve stimulation
Sites
1 site in 1 country
- Wellness, Health and Research Facility at UABBirmingham, Alabama, United States